Goldman Sachs
VBIV

Goldman Sachs’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Goldman Sachs’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,189
Closed -$18.8K – 6007
2024
Q1 		$18.8K Buy
31,189
+825
+3% +$506 ﹤0.01% 5396
2023
Q4 		$17.8K Buy
+30,364
New +$18.3K ﹤0.01% 5449
2023
Q2 		– Sell
-6,555
Closed -$59.6K – 6159
2023
Q1 		$59.6K Buy
6,555
+576
+10% +$8.16K ﹤0.01% 5528
2022
Q4 		$70.1K Sell
5,979
-4,079
-41% -$71.9K ﹤0.01% 5547
2022
Q3 		$213K Sell
10,058
-30,259
-75% -$816K ﹤0.01% 5446
2022
Q2 		$978K Buy
40,317
+6,864
+21% +$234K ﹤0.01% 4627
2022
Q1 		$1.67M Sell
33,453
-4,999
-13% -$247K ﹤0.01% 4398
2021
Q4 		$2.7M Buy
38,452
+27,272
+244% +$2.3M ﹤0.01% 3984
2021
Q3 		$1.04M Buy
11,180
+4,440
+66% +$422K ﹤0.01% 4708
2021
Q2 		$677K Buy
6,740
+1,213
+22% +$118K ﹤0.01% 5029
2021
Q1 		$516K Buy
5,527
+911
+20% +$92.4K ﹤0.01% 5092
2020
Q4 		$381K Sell
4,616
-6,321
-58% -$539K ﹤0.01% 4768
2020
Q3 		$938K Buy
10,937
+8,336
+320% +$971K ﹤0.01% 4127
2020
Q2 		$242K Sell
2,601
-2,766
-52% -$152K ﹤0.01% 4719
2020
Q1 		$152K Buy
5,367
+2,051
+62% +$79.7K ﹤0.01% 4800
2019
Q4 		$137K Buy
+3,316
New +$72.6K ﹤0.01% 4994
2019
Q3 		– Sell
-18,321
Closed -$643K – 5429
2019
Q2 		$643K Buy
+18,321
New +$993K ﹤0.01% 4273
2018
Q4 		– Sell
-1,396
Closed -$101K – 5773
2018
Q3 		$101K Sell
1,396
-3,583
-72% -$236K ﹤0.01% 5137
2018
Q2 		$411K Buy
+4,979
New +$481K ﹤0.01% 4619
2017
Q2 		– Sell
-2,323
Closed -$383K – 7027
2017
Q1 		$383K Buy
+2,323
New +$314K ﹤0.01% 5252
2016
Q2 		– Sell
-1,215
Closed -$86K – 7294
2016
Q1 		$86K Buy
1,215
+447
+58% +$29.6K ﹤0.01% 6149
2015
Q4 		$56K Sell
768
-5
-0.6% -$382 ﹤0.01% 6484
2015
Q3 		$61K Buy
+773
New +$61.3K ﹤0.01% 6717
2015
Q1 		– Sell
-806
Closed -$81K – 7330
2014
Q4 		$81K Buy
+806
New +$63.6K ﹤0.01% 6655

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs's VBIV Position: Q2 2024 in Review

Goldman Sachs sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2024, closing a stake of 31,189 shares — an estimated $18.8K sold.

Goldman Sachs first reported a position in VBIV in Q4 2014 and held it in 24 quarters. The position peaked at $2.7M in Q4 2021. 41 funds tracked by Wall St. Rank hold VBIV as of Q2 2024.

  • Goldman Sachs reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2024 after selling out during the quarter.
  • Goldman Sachs sold 31,189 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2024, an estimated $18.8K.
  • Goldman Sachs first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2014 and held it in 24 quarters.
  • Goldman Sachs's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $2.7M in Q4 2021.
  • 41 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.